We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49 | -1.65% | 29.26 | 29.25 | 29.52 | 29.73 | 29.20 | 29.71 | 6,646,430 | 22:20:00 |
From May 2019 to May 2024
By Cristina Roca
Roche Holding AG (ROG.EB) said Monday that the chief executive of its Roche Pharmaceuticals business is leaving at the end of the year, and named his successor.
The Swiss pharmaceuticals company said current CEO Daniel O'Day will step down as of Dec. 31, and said it was appointing William Anderson to the post effective Jan. 1.
Roche said Mr. Anderson will also become a member of its corporate executive committee.
Mr. Anderson is currently chief executive of Genentech, a Roche subsidiary company. He has worked for Roche since 2006.
Separately, Roche said it was proposing Hans Clevers for election to its board of directors. Mr. Clevers is a professor of molecular genetics at University Medical Center Utrecht, the company said.
Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca
(END) Dow Jones Newswires
December 10, 2018 01:35 ET (06:35 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
